The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 14, 2019

Filed:

Jun. 25, 2017
Applicants:

Ram Isanaka, Warren, NJ (US);

Jesse Jaynes, Auburn, AL (US);

Inventors:

Ram Isanaka, Warren, NJ (US);

Jesse Jaynes, Auburn, AL (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/08 (2019.01); A61K 38/00 (2006.01); A61K 47/02 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 9/06 (2006.01); A61Q 19/00 (2006.01); C07K 14/00 (2006.01); A61K 47/18 (2017.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/06 (2013.01); A61K 9/0014 (2013.01); A61K 38/00 (2013.01); A61K 38/08 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/24 (2013.01); A61K 47/02 (2013.01);
Abstract

Antimicrobial peptides represent a relatively new discovery in the immune system pathway. Recent designs of synthetically engineered antimicrobial peptides have demonstrated increased potency and efficacy/tolerability, enhanced specificity, and reduced toxicity in comparison. One such peptide, XYLENTRA®, has shown/demonstrated significant promise from significant in vitro studies against a large + pathogens. Additionally, extensive animal studies have shown that the XYLENTRA® is an antimicrobial peptide against a large number of pathogens. The XYLENTRA® peptide is also solute resistant. The peptide XYLENTRA® has shown/demonstrated significant antibacterial activity on test organismsMTCC 96 and. MTCC741. A substantial decrease in the microbial population level was observed in animals treated with peptide using the protocol described in detail in the application.


Find Patent Forward Citations

Loading…